Related Experiment Video
Updated: Nov 26, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Emerging Topics in Heart Failure: New Paradigms in Cardiac Amyloidosis
Marcus Vinicius Simões1, Silvia Marinho Martins Alves2, Fabio Fernandes3
1Divisão de Cardiologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, SP - Brasil.
Insights
Cardiac amyloidosis (CA), especially the transthyretin-mediated form, is an underdiagnosed cause of heart failure with preserved ejection fraction (HFpEF) in older adults. New therapies are emerging for this condition.
Area of Science:
- Cardiology
- Cardiovascular Diseases
- Amyloidosis
Background:
- Cardiac amyloidosis (CA) is increasingly recognized as a significant, often underdiagnosed, contributor to heart failure.
- Transthyretin-mediated amyloidosis (ATTR-CA) is a primary subtype, frequently implicated in heart failure with preserved ejection fraction (HFpEF), particularly in elderly populations.
Abstract:
Recent evidence suggests cardiac amyloidosis (CA) is a mostly underdiagnosed condition, particularly in the transthyretin-mediated form, and is a frequent cause of heart failure with preserved ejection fraction (HFpEF) in the elderly. New paradigms about CA also involve the development of disease-modifying specific therapies. This article summarizes these new concepts.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
08:49Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology
Cardiomyopathy V: Interprofessional Care
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy